{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:50:49Z","timestamp":1791204649083,"version":"4.2.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102884"],"award-info":[{"award-number":["82102884"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002764"],"award-info":[{"award-number":["82002764"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272628"],"award-info":[{"award-number":["82272628"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172717"],"award-info":[{"award-number":["82172717"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-024-02744-6","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T04:02:16Z","timestamp":1723521736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer"],"prefix":"10.1186","volume":"22","author":[{"given":"Ying","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songwei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"issue":"1","key":"2744_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","volume":"14","author":"BM Reid","year":"2017","unstructured":"Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9\u201332.","journal-title":"Cancer Biol Med"},{"issue":"Suppl 1","key":"2744_CR2","doi-asserted-by":"publisher","first-page":"i11","DOI":"10.1093\/annonc\/mdw084","volume":"27","author":"G Coukos","year":"2016","unstructured":"Coukos G, Tanyi J, Kandalaft LE. Opportunities in immunotherapy of ovarian cancer. Ann Oncol. 2016;27(Suppl 1):i11\u20135.","journal-title":"Ann Oncol"},{"issue":"34","key":"2744_CR3","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi J, et al. Safety and Antitumor activity of Anti-PD-1 antibody, Nivolumab, in patients with platinum-resistant ovarian Cancer. J Clin Oncol. 2015;33(34):4015\u201322.","journal-title":"J Clin Oncol"},{"key":"2744_CR4","unstructured":"Matulonis UA et al. Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer. J Clin Oncol, 2020. 38(15)."},{"issue":"2","key":"2744_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","volume":"152","author":"A Varga","year":"2019","unstructured":"Varga A, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028. Gynecol Oncol. 2019;152(2):243\u201350.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2744_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","volume":"5","author":"ML Disis","year":"2019","unstructured":"Disis ML, et al. Efficacy and safety of Avelumab for patients with recurrent or refractory ovarian Cancer phase 1b results from the JAVELIN Solid Tumor Trial. Jama Oncol. 2019;5(3):393\u2013401.","journal-title":"Jama Oncol"},{"issue":"20","key":"2744_CR7","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw MH, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20):6106\u201315.","journal-title":"Clin Cancer Res"},{"key":"2744_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40425-015-0051-7","volume":"3","author":"C Chester","year":"2015","unstructured":"Chester C, et al. Immunotherapeutic approaches to ovarian cancer treatment. J Immunother Cancer. 2015;3:7.","journal-title":"J Immunother Cancer"},{"key":"2744_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.coi.2018.03.001","volume":"51","author":"H Maeng","year":"2018","unstructured":"Maeng H, Terabe M, Berzofsky JA. Cancer vaccines: translation from mice to human clinical trials. Curr Opin Immunol. 2018;51:111\u201322.","journal-title":"Curr Opin Immunol"},{"key":"2744_CR10","first-page":"CD007287","volume":"9","author":"ST Paijens","year":"2018","unstructured":"Paijens ST, et al. Antigen-specific active immunotherapy for ovarian cancer. Cochrane Database Syst Rev. 2018;9:CD007287.","journal-title":"Cochrane Database Syst Rev"},{"key":"2744_CR11","first-page":"16","volume":"148","author":"W Song","year":"2017","unstructured":"Song W, Musetti SN, Huang L. Nanomaterials cancer Immunotherapy Biomaterials. 2017;148:16\u201330.","journal-title":"Nanomaterials cancer Immunotherapy Biomaterials"},{"issue":"3","key":"2744_CR12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1080\/21645515.2015.1102804","volume":"12","author":"M Allahyari","year":"2016","unstructured":"Allahyari M, Mohit E. Peptide\/protein vaccine delivery system based on PLGA particles. Hum Vaccin Immunother. 2016;12(3):806\u201328.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"2744_CR13","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1021\/acsnano.7b09041","volume":"12","author":"R Yang","year":"2018","unstructured":"Yang R, et al. Cancer Cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination. ACS Nano. 2018;12(6):5121\u20139.","journal-title":"ACS Nano"},{"issue":"1","key":"2744_CR14","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1038\/s41467-021-23244-3","volume":"12","author":"J Koerner","year":"2021","unstructured":"Koerner J, et al. PLGA-particle vaccine carrying TLR3\/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy. Nat Commun. 2021;12(1):2935.","journal-title":"Nat Commun"},{"issue":"9","key":"2744_CR15","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/nnano.2017.113","volume":"12","author":"Y Min","year":"2017","unstructured":"Min Y, et al. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat Nanotechnol. 2017;12(9):877\u201382.","journal-title":"Nat Nanotechnol"},{"key":"2744_CR16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.7150\/jca.1.230","volume":"1","author":"PG Lokhov","year":"2010","unstructured":"Lokhov PG, Balashova EE. Cellular cancer vaccines: an update on the development of vaccines generated from cell surface antigens. J Cancer. 2010;1:230\u201341.","journal-title":"J Cancer"},{"issue":"17","key":"2744_CR17","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-08-0233","volume":"14","author":"W Yang","year":"2008","unstructured":"Yang W, et al. TMTP1, a novel tumor-homing peptide specifically targeting metastasis. Clin Cancer Res. 2008;14(17):5494\u2013502.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2744_CR18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jconrel.2012.05.002","volume":"161","author":"R Liu","year":"2012","unstructured":"Liu R, et al. Enhanced targeted anticancer effects and inhibition of tumor metastasis by the TMTP1 compound peptide TMTP1-TAT-NBD. J Control Release. 2012;161(3):893\u2013902.","journal-title":"J Control Release"},{"issue":"1","key":"2744_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1021\/mp300125k","volume":"10","author":"X Ma","year":"2013","unstructured":"Ma X, et al. DT390-triTMTP1, a novel fusion protein of diphtheria toxin with tandem repeat TMTP1 peptide, preferentially targets metastatic tumors. Mol Pharm. 2013;10(1):115\u201326.","journal-title":"Mol Pharm"},{"issue":"2","key":"2744_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00109-013-1093-2","volume":"92","author":"R Liu","year":"2014","unstructured":"Liu R, et al. The novel fusion protein sTRAIL-TMTP1 exhibits a targeted inhibition of primary tumors and metastases. J Mol Med (Berl). 2014;92(2):165\u201375.","journal-title":"J Mol Med (Berl)"},{"issue":"3","key":"2744_CR21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.nucmedbio.2014.11.001","volume":"42","author":"F Li","year":"2015","unstructured":"Li F, et al. Evaluation of (99m)Tc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT. Nucl Med Biol. 2015;42(3):256\u201362.","journal-title":"Nucl Med Biol"},{"issue":"1\u20132","key":"2744_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ijpharm.2016.01.039","volume":"500","author":"JW McBride","year":"2016","unstructured":"McBride JW, et al. Development of TMTP-1 targeted designer biopolymers for gene delivery to prostate cancer. Int J Pharm. 2016;500(1\u20132):144\u201353.","journal-title":"Int J Pharm"},{"issue":"12","key":"2744_CR23","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1021\/acs.bioconjchem.8b00756","volume":"29","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, et al. A Novel Near-Infrared fluorescent probe TMTP1-PEG4-ICG for in vivo Tumor Imaging. Bioconjug Chem. 2018;29(12):4119\u201326.","journal-title":"Bioconjug Chem"},{"issue":"24","key":"2744_CR24","doi-asserted-by":"publisher","first-page":"7325","DOI":"10.7150\/thno.35346","volume":"9","author":"R Wei","year":"2019","unstructured":"Wei R, et al. TMTP1-modified Indocyanine Green-loaded polymeric micelles for targeted imaging of Cervical Cancer and Metastasis Sentinel Lymph Node in vivo. Theranostics. 2019;9(24):7325\u201344.","journal-title":"Theranostics"},{"key":"2744_CR25","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.2147\/IJN.S298252","volume":"16","author":"G Jiang","year":"2021","unstructured":"Jiang G, et al. TMTP1-Modified, Tumor Microenvironment Responsive nanoparticles Co-deliver Cisplatin and Paclitaxel Prodrugs for Effective Cervical Cancer Therapy. Int J Nanomed. 2021;16:4087\u2013104.","journal-title":"Int J Nanomed"},{"issue":"8","key":"2744_CR26","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.2174\/0929867325666171123204851","volume":"27","author":"AC Conibear","year":"2020","unstructured":"Conibear AC, et al. Recent advances in peptide-based approaches for Cancer Treatment. Curr Med Chem. 2020;27(8):1174\u2013205.","journal-title":"Curr Med Chem"},{"issue":"28","key":"2744_CR27","doi-asserted-by":"publisher","first-page":"9778","DOI":"10.1021\/acs.analchem.1c01254","volume":"93","author":"H Zhong","year":"2021","unstructured":"Zhong H, et al. Engineering peptide-functionalized Biomimetic Nanointerfaces for Synergetic capture of circulating Tumor cells in an EpCAM-Independent manner. Anal Chem. 2021;93(28):9778\u201387.","journal-title":"Anal Chem"},{"key":"2744_CR28","doi-asserted-by":"publisher","first-page":"463274","DOI":"10.1016\/j.chroma.2022.463274","volume":"1676","author":"J Ren","year":"2022","unstructured":"Ren J, et al. An engineered peptide tag-specific nanobody for immunoaffinity chromatography application enabling efficient product recovery at mild conditions. J Chromatogr A. 2022;1676:463274.","journal-title":"J Chromatogr A"},{"issue":"2","key":"2744_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2144\/000114195","volume":"57","author":"DB Wronska","year":"2014","unstructured":"Wronska DB, et al. Peptide-conjugated glass slides for selective capture and purification of diagnostic cells: applications in urine cytology. Biotechniques. 2014;57(2):63\u201371.","journal-title":"Biotechniques"},{"issue":"12","key":"2744_CR30","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko DV, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860\u201375.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2744_CR31","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1002\/ijc.28515","volume":"134","author":"M Paroli","year":"2014","unstructured":"Paroli M, et al. Discovery of chemotherapy-associated ovarian cancer antigens by interrogating memory T cells. Int J Cancer. 2014;134(8):1823\u201334.","journal-title":"Int J Cancer"},{"issue":"1","key":"2744_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/cdd.2013.67","volume":"21","author":"L Bracci","year":"2014","unstructured":"Bracci L, et al. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21(1):15\u201325.","journal-title":"Cell Death Differ"},{"issue":"12","key":"2744_CR33","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/nm.3409","volume":"19","author":"SG Reed","year":"2013","unstructured":"Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013;19(12):1597\u2013608.","journal-title":"Nat Med"},{"issue":"6","key":"2744_CR34","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1517\/17425247.5.6.703","volume":"5","author":"JM Irache","year":"2008","unstructured":"Irache JM, et al. Mannose-targeted systems for the delivery of therapeutics. Expert Opin Drug Deliv. 2008;5(6):703\u201324.","journal-title":"Expert Opin Drug Deliv"},{"issue":"10","key":"2744_CR35","doi-asserted-by":"publisher","first-page":"7226","DOI":"10.1021\/acs.nanolett.9b02834","volume":"19","author":"YN Zhang","year":"2019","unstructured":"Zhang YN, et al. Nanoparticle size influences Antigen Retention and Presentation in Lymph Node Follicles for Humoral Immunity. Nano Lett. 2019;19(10):7226\u201335.","journal-title":"Nano Lett"},{"issue":"11","key":"2744_CR36","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","volume":"10","author":"MF Bachmann","year":"2010","unstructured":"Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787\u201396.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2744_CR37","doi-asserted-by":"publisher","first-page":"8ra19","DOI":"10.1126\/scitranslmed.3000359","volume":"1","author":"OA Ali","year":"2009","unstructured":"Ali OA, et al. In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci Transl Med. 2009;1(8):8ra19.","journal-title":"Sci Transl Med"},{"issue":"8","key":"2744_CR38","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1021\/ja016727k","volume":"124","author":"CW Cairo","year":"2002","unstructured":"Cairo CW, et al. Control of multivalent interactions by binding epitope density. J Am Chem Soc. 2002;124(8):1615\u20139.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"2744_CR39","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1021\/bc025598+","volume":"14","author":"E Jule","year":"2003","unstructured":"Jule E, Nagasaki Y, Kataoka K. Lactose-installed poly(ethylene glycol)-poly(d,l-lactide) block copolymer micelles exhibit fast-rate binding and high affinity toward a protein bed simulating a cell surface. A surface plasmon resonance study. Bioconjug Chem. 2003;14(1):177\u201386.","journal-title":"Bioconjug Chem"},{"issue":"1","key":"2744_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3109\/10611861003663531","volume":"19","author":"J Yin","year":"2011","unstructured":"Yin J, et al. Cyclic RGDyK conjugation facilitates intracellular drug delivery of polymeric micelles to integrin-overexpressing tumor cells and neovasculature. J Drug Target. 2011;19(1):25\u201336.","journal-title":"J Drug Target"},{"issue":"5","key":"2744_CR41","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","volume":"72","author":"JC Castle","year":"2012","unstructured":"Castle JC, et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012;72(5):1081\u201391.","journal-title":"Cancer Res"},{"issue":"10","key":"2744_CR42","doi-asserted-by":"publisher","first-page":"1802157","DOI":"10.1002\/advs.201802157","volume":"6","author":"M Wang","year":"2019","unstructured":"Wang M, et al. NIR-Triggered Phototherapy and Immunotherapy via an Antigen-capturing nanoplatform for metastatic Cancer treatment. Adv Sci (Weinh). 2019;6(10):1802157.","journal-title":"Adv Sci (Weinh)"},{"issue":"9","key":"2744_CR43","doi-asserted-by":"publisher","first-page":"15226","DOI":"10.1021\/acsnano.2c06560","volume":"16","author":"L Jin","year":"2022","unstructured":"Jin L, et al. In situ programming of Nanovaccines for Lymph Node-targeted delivery and Cancer immunotherapy. ACS Nano. 2022;16(9):15226\u201336.","journal-title":"ACS Nano"},{"key":"2744_CR44","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/B978-0-12-391858-1.00008-3","volume":"509","author":"LJ Cruz","year":"2012","unstructured":"Cruz LJ, et al. Targeting nanoparticles to dendritic cells for immunotherapy. Methods Enzymol. 2012;509:143\u201363.","journal-title":"Methods Enzymol"},{"key":"2744_CR45","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijbiomac.2021.07.141","volume":"187","author":"Y Shi","year":"2021","unstructured":"Shi Y, et al. Dextran-polylactide micelles loaded with doxorubicin and DiR for image-guided chemo-photothermal tumor therapy. Int J Biol Macromol. 2021;187:296\u2013308.","journal-title":"Int J Biol Macromol"},{"issue":"2","key":"2744_CR46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","volume":"19","author":"DK Armstrong","year":"2021","unstructured":"Armstrong DK, et al. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(2):191\u2013226.","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"2744_CR47","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi J, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8\u2009+\u2009T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2744_CR48","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/cei.13255","volume":"195","author":"A Pawlowska","year":"2019","unstructured":"Pawlowska A, et al. Immunotherapies based on PD-1\/PD-L1 pathway inhibitors in ovarian cancer treatment. Clin Exp Immunol. 2019;195(3):334\u201344.","journal-title":"Clin Exp Immunol"},{"issue":"16","key":"2744_CR49","doi-asserted-by":"publisher","first-page":"e1908185","DOI":"10.1002\/adma.201908185","volume":"32","author":"Q Chen","year":"2020","unstructured":"Chen Q, et al. A hybrid eukaryotic-prokaryotic nanoplatform with Photothermal modality for enhanced Antitumor Vaccination. Adv Mater. 2020;32(16):e1908185.","journal-title":"Adv Mater"},{"key":"2744_CR50","doi-asserted-by":"crossref","unstructured":"Tanyi JL et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med, 2018. 10(436).","DOI":"10.1126\/scitranslmed.aao5931"},{"issue":"15","key":"2744_CR51","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1073\/pnas.1117208109","volume":"109","author":"K Odunsi","year":"2012","unstructured":"Odunsi K, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A. 2012;109(15):5797\u2013802.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"31","key":"2744_CR52","doi-asserted-by":"publisher","first-page":"32228","DOI":"10.18632\/oncotarget.4772","volume":"6","author":"EM Dijkgraaf","year":"2015","unstructured":"Dijkgraaf EM, et al. A phase 1\/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget. 2015;6(31):32228\u201343.","journal-title":"Oncotarget"},{"issue":"5","key":"2744_CR53","doi-asserted-by":"publisher","first-page":"E670","DOI":"10.1002\/ijc.27388","volume":"131","author":"R Vermeij","year":"2012","unstructured":"Vermeij R, et al. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study. Int J Cancer. 2012;131(5):E670\u201380.","journal-title":"Int J Cancer"},{"key":"2744_CR54","first-page":"187","volume":"6","author":"L Bezu","year":"2015","unstructured":"Bezu L, et al. Combinatorial strategies for the induction of immunogenic cell death. Front Immunol. 2015;6:187.","journal-title":"Front Immunol"},{"key":"2744_CR55","doi-asserted-by":"crossref","unstructured":"McCloskey CW et al. Ovarian Cancer immunotherapy: preclinical models and emerging therapeutics. Cancers (Basel), 2018. 10(8).","DOI":"10.3390\/cancers10080244"},{"issue":"11","key":"2744_CR56","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/14760584.2018.1541743","volume":"17","author":"JL Tanyi","year":"2018","unstructured":"Tanyi JL, George E. Personalized vaccination against ovarian cancer: what are the possibilities? Expert Rev Vaccines. 2018;17(11):955\u20138.","journal-title":"Expert Rev Vaccines"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-024-02744-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-024-02744-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-024-02744-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T16:04:43Z","timestamp":1723565083000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-024-02744-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2744"],"URL":"https:\/\/doi.org\/10.1186\/s12951-024-02744-6","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"11 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"483"}}